Entresto

Active Ingredient(s): Sacubitril + Valsartan
FDA Approved: * July 7, 2015
Pharm Company: * NOVARTIS PHARMS CORP
Category: Blood Pressure

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Entresto Overview

Sacubitril/valsartan, sold under the brand name Entresto among others, is a fixed-dose combination medication for use in heart failure. It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan. It is recommended for use as a replacement for an ACE inhibitor or an angiotensin receptor blocker in people with heart failure with reduced ejection fraction.[7] Potential side effects include angioedema, kidney problems, and low blood pressure....

Read more Entresto Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Valsartan/sacubitril

Recent Entresto Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Sacubitril + Valsartan
  • Tablet: 24mg + 26mg, 49mg + 51mg, 97mg + 103mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Entresto: (3 results)

Sorted by National Drug Code
  • 0078-0659 Entresto Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
  • 0078-0696 Entresto Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
  • 0078-0777 Entresto Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation

Drugs with one or more similar ingredients: (14 results)